Neuren Pharmaceuticals (ASX:NEU) said its Nasdaq-listed partner Acadia Pharmaceuticals completed the sale of a rare pediatric disease priority review voucher for $150 million, according to a Thursday filing with the Australian bourse.

The voucher was granted by the US Food and Drug Administration after the approval of Daybue for the treatment of Rett syndrome, the filing said.

The company is entitled to one-third of the proceeds under its license agreement with Acadia, according to the filing.

Price (AUD): $13.42, Change: $-0.02, Percent Change: -0.15%